Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;53(7):e14086.
doi: 10.1111/and.14086. Epub 2021 May 5.

The clinical significance of abnormal ejaculation by silodosin. Is it important?

Murat Akgül  1 , Cenk Yazıcı  1 , Timuçin Şipal  2 , Ersan Arda  3
Affiliations

The clinical significance of abnormal ejaculation by silodosin. Is it important?

Murat Akgül et al. Andrologia. 2021 Aug.

Abstract

We aimed to evaluate the effect of the abnormal ejaculation (AEj) on patients using silodosin in terms of drug cessation. We also analysed the possible factors that may affect the decisions of patients with AEj to proceed or change their medication. The patients (n = 118) treated with silodosin 8 mg daily were prospectively analysed. In order to evaluate the erectile function, ejaculatory function, depression and sexual satisfaction; IIEF, MSHQ-EjD, Beck's depression and Golombok-Rust questionnaires were given to patients respectively. Patients were re-evaluated at the 3rd month of their treatment. The rate of AEj was 52.5%. Nearly 42% of the patients with AEj desired to stop their medication whereas it was 7.1% at patients without AEj (p < .001). The pre-treatment International Prostate Symptom Score (IPSS) and the decrease in IPSS score were significantly lower in patients who demand to stop their treatment (p < .05). AEj was significantly higher in patients who wanted to stop their medication (p < .001). Even if they had an AEj, patients who were happy with the clinical efficacy of silodosin did not want to change their drug. In addition to this, pre-treatment ejaculatory status was an important indicator for patients to decide drug cessation due to AEj side effect of silodosin.

Keywords: abnormal ejaculation; benign prostate hyperplasia; silodosin; α-blockers.

PubMed Disclaimer

References

REFERENCES

    1. Bhat, G. S., & Shastry, A. (2020). A prospective double-blind, randomized, placebo-controlled study to evaluate the efficacy of silodosin 8 mg as an on-demand, reversible, nonhormonal oral contraceptive for males: A pilot study. World Journal of Urology, 38(3), 747-751. https://doi.org/10.1007/s00345-019-02806-7
    1. Chapple, C. R., Montorsi, F., Tammela, T. L., Wirth, M., Koldewijn, E., & Fernández Fernández, E. (2011). European Silodosin Study Group Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo-and active-controlled clinical trial performed in Europe. European Urology, 59(3), 342-352. https://doi.org/10.1016/j.eururo.2010.10.046
    1. Ding, H., Du, W., Hou, Z. Z., Wang, H. Z., & Wang, Z. P. (2013). Silodosin is effective for treatment of LUTS in men with BPH: A systematic review. Asian Journal of Andrology, 15(1), 121. https://doi.org/10.1038/aja.2012.102
    1. Fusco, F., Palmieri, A., Ficarra, V., Giannarini, G., Novara, G., Longo, N., Verze, P., Creta, M., & Mirone, V. (2016). α1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: A systematic review and meta-analysis of urodynamic studies. European Urology, 69(6), 1091-1101. https://doi.org/10.1016/j.eururo.2015.12.034
    1. Gacci, M., Ficarra, V., Sebastianelli, A., Corona, G., Serni, S., Shariat, S. F., Maggi, M., Zattoni, F., Carini, M., & Novara, G. (2014). Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: A systematic review and meta-analysis. The Journal of Sexual Medicine, 11(6), 1554-1566. https://doi.org/10.1111/jsm.12525

LinkOut - more resources